FORM 4

Instruction 1(b).

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Vashington,	D.C. 2054	9
-------------	-----------	---

to Section 16. Form 4 or Form 5	STATEMENT OF CHANGES IN BENEFICIAL	OWNERSHIP
obligations may continue. See		

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Mayer Arie					2. Issuer Name and Ticker or Trading Symbol ORAMED PHARMACEUTICALS INC. [ ORMP]										k all app Direc			10% O	wner
(Last)	(Fi AN STREI	,	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 04/03/2023										Officer (give title below)		Other ( below)	specify
(Street)  KFAR SABA L3 4428890  (City) (State) (Zip)			)	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Indi Line) X	· ·					
(6.9)	(0.	(-				Check t	his box	to indic	cate that	a trans	tion Indi	ade pur	suant to			uction or writt	en pla	in that is inte	nded to
		Table	I - No	n-Deriva	tive S	Secu	rities	Acq	uired,	Dis	posed of	, or E	Benef	icially	/ Own	ed			
1. Title of Security (Instr. 3)  2. Transact Date (Month/Day				y/Year) Execu		Deemed tution Date, y hth/Day/Year)				es Acquired (A) Of (D) (Instr. 3,		4 and Secu Bene Owne		cially I Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	(A) (D)	or Pri	ice		ction(s) 3 and 4)			(Instr. 4)
Common	Stock		04/03/2023 P 5,009 A \$2.22 <sup>(1)</sup>						2.	23,009		D							
Common	Common Stock 04/04/2					2023					3,800	A	. \$	2.21	26,809		D		
		Tal									osed of, convertib				Owne	d			
1. Title of Derivative Security (Instr. 3)	rative or Exercise (Month/Day/Year)  Trice of Derivative Security  Date (Month/Day/Year)  Execution Date, if any (Month/Day/Year)		4. Transa Code ( 8)	Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		rative rities ired r osed ) : 3, 4	6. Date Exercisable and Expiration Date (Month/Day/Year)  Date Expiration Exercisable Date			7. Title and Amount of Securities Underlying Derivative Security (Instra 3 and 4)  Amount or Number of Title Shares		nt er		9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	,	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		

## **Explanation of Responses:**

## Remarks:

/s/ Arie Mayer

04/04/2023

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

<sup>1.</sup> The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$2.17 to \$2.22, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the above range